GeneDx Holdings Corp. (WGS) Form 8-K — Nov 18, 2026
GeneDx (Nasdaq: WGS) announced that CEO Katherine Stueland will step down and resign from the Board when Everett Cunningham takes over as CEO, effective on or before December 15, 2026. Stueland will stay as an Executive Advisor through January 31, 2027, with her March 2027 RSU vesting accelerated in lieu of salary severance. Cunningham, most recently CEO of Quanterix, brings more than 35 years of diagnostics and commercial leadership experience from Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics and Pfizer. He receives a $750,000 base salary, a $1,050,000 sign-on bonus, and $10.0 million each in time-based RSUs and price-hurdle PRSUs.
Key figures
- Sign on bonus
- $1,050,000
- Transition date
- on or before December 15, 2026
- Stueland exit date
- January 31, 2027
- New ceo base salary
- $750,000
- Initial rsu award value
- $10.0 million
- Initial prsu award value
- $10.0 million
- Target bonus pct of base
- 100%
- Annual refresh prsu target value
- $4,000,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.